Juliette L. Forster

Juliette L. Forster

Auto-generated profile, based on publicly available information

Juliette L. Forster

Department of Biosystems Science and Engineering, ETH Zürich, 4056 Basel, Switzerland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2025 in Science Advances
Verified
Journal Article
Open access
RCRocío Castellanos-Rueda
Rocío Castellanos-Rueda
KWKai-Ling K. Wang
Kai-Ling K. Wang
JFJuliette L. Forster
Juliette L. Forster
ADAlice Driessen
Alice Driessen
JFJessica A. Frank
Jessica A. Frank
SRSai T. Reddy
Sai T. Reddy
Chimeric antigen receptor (CAR) T cells offer a promising cancer treatment, yet challenges such as limited T cell persistence hinder efficacy. Given its critical role in modulating T cell responses, it is crucial to understand how the CAR signaling architecture influences T cell function. Here, we designed a combinatorial CAR signaling domain library and performed repeated antigen stimulation assays, pooled screens, and single-cell sequencing to systematically investigate the impact of modifying CAR signaling domains on T cell activation and persistence. Our data reveal the predominant influence of membrane-proximal domains in driving T cell phenotype. Notably, CD40 costimulation was crucial for fostering robust and lasting T cell responses. Furthermore, we correlated in vitro generated CAR T cell phenotypes with clinical outcomes in patients treated with CAR T therapy, establishing the foundation for a clinically informed screening approach. This work deepens our understanding of CAR T cell biology and may guide future CAR engineering efforts.

27 July 2025 in bioRxiv
Verified
Preprint
Open access
KHKai-Lin Hong
Kai-Lin Hong
BGBeichen Gao
Beichen Gao
LSLucas Stalder
Lucas Stalder
RERoy A. Ehling
Roy A. Ehling
MHMarton Horvath
Marton Horvath
SRSai T. Reddy
Sai T. Reddy
TCR specificity to peptide-HLA antigens is central to immunology, impacting responses in infection, autoimmunity and cancer. Achieving precise recognition while avoiding off-target reactivity is critical for effective immunity and safe therapeutic interventions. Comprehensive, proteome-wide specificity profiling of TCRs is challenging with current methods, which notably lack integrated machine learning for large-scale analysis. Here, we report a synthetic immune cell system coupled with machine learning to enable TCR functional and specificity mapping of peptide-HLA antigens at proteome-scale. Multi-step immunogenomic engineering of synthetic antigen-presenting cells (APCs) was performed to enable stable mono-allelic integration and precise display of peptide antigens and HLA class I from a defined genomic locus, ensuring genomically-encoded antigen presentation. Compatible with a synthetic TCR displaying T cell system, this platform incorporates a fluorescent reporter of cytokine-mediated signaling for real-time activation detection in both synthetic APCs and T cells. We combined this screening with diverse peptide antigen libraries and deep sequencing to train supervised machine learning models. These models were applied to predict TCR specificity to peptide-HLA antigens across the entire human proteome. Experimental validation confirmed novel off-targets for therapeutic TCR candidates, including for a clinically-approved TCR therapeutic. This integrated synthetic immune cell and machine learning approach provides unprecedented proteome-wide peptide-HLA specificity mapping to support the development of safer TCR-based therapies. One sentence summary: We present a synthetic immune cell platform integrated with machine learning that enables prediction of TCR specificity to peptide-HLA antigens at proteome-scale.